Generative AI: Separating Hype from Enterprise Value
Two years after ChatGPT's launch sparked global fascination, the generative AI landscape has matured dramatically. The experimental phase is over.
Read this piece§ 01 / 02
The archive
Page 3 of 3, newest first.
Every piece we have published is listed in order across these pages, each with the line that says what it covers. The newest pieces are on the pages before this one.
The full index
Page 3 of 3, newest first.
Gene Therapy Commercial Viability: From Approval to Patient Access
Approval is not the finish line for a gene therapy. Manufacturing, site-of-care access, payment architecture, and durability are separate commercial risks.
Read this pieceFDA Digital Health Guidance: Regulatory Clarity Accelerates Innovation
The FDA's predetermined change control plan lets an AI-enabled device keep learning after clearance without refiling for every update. That changes what's investable.
Read this pieceThe Management Fee, and What It Actually Pays For
A management fee is an operating budget. Read it function by function, then against the step-downs and offsets that shrink it, under ILPA Principles 3.0 and the Advisers Act.
Read this pieceESG Integration in Investment Due Diligence
Generic ESG checklists measure the wrong risks in healthcare. Materiality-driven diligence tests clinical ethics, data privacy, pricing, supply risk and governance instead.
Read this pieceFund of Funds, and Why an Emerging Manager Meets One
A fund of funds is how major public pension emerging-manager programs reach first-time private equity managers. What it underwrites in a first fund, and what it asks for.
Read this pieceThe Hurdle Rate, Defined Against Market Convention
The hurdle rate centers on 8% in private equity, but the compounding basis, the start of the clock and the catch-up decide what it protects.
Read this pieceDigital Health: From Telemedicine to AI Diagnostics
Model accuracy is table stakes. AI diagnostic winners are decided by prospective validation, workflow integration, and who bears liability for a miss.
Read this pieceDemocratizing Healthcare Access: Digital Platforms Bridging Rural Care Gaps
Rural healthcare access is a reimbursement and logistics problem, not a product problem. Broadband, hospital closures, and billing codes set the real ceiling.
Read this pieceCross-Border Investment: Navigating Complexity for Returns
A company spanning borders faces five separate underwriting problems: screening, data residency, treaty structure, currency exposure, and enforcement risk.
Read this pieceCarve-Out Acquisitions: The Execution Playbook
A carve-out prices at a discount because separation is real work, not margin. Here is what a TSA, stranded costs, and untangled shared IP actually cost a buyer.
Read this pieceBuilding Value Beyond Capital: Our Force Multiplier Approach
LeverVenture's Force Multiplier Approach pairs capital with operational support across go-to-market, operations, talent, M&A and exit preparation.
Read this pieceBiotech Funding Environment: Post-IPO Window Analysis
When the biotech IPO window is shut, capital doesn't disappear — it changes shape. Which financing instrument a company reaches for is itself diligence.
Read this pieceIndustry Case Study: Ather Energy's Electric Mobility Revolution
Ather Energy, India's electric scooter maker, reached a $1.37 billion valuation as of mid-2025 through vertical integration and a 1,000+ point fast-charging network.
Read this pieceAI Implementation Framework for Growth Companies
Most companies have now run an AI pilot. Far fewer have put one into production and kept it there.
Read this pieceGrowth Equity Firms in AI Healthcare: The Operator's Playbook for Raising Growth Capital in 2025
A founder-level guide to growth equity firms investing in AI healthcare — due diligence frameworks, valuation drivers, reimbursement risk, and exit pathways covered.
Read this piece§ 02 / 02
Research
The State of Growth Equity, 2026 edition.
The first edition of our read on the passage between venture capital and private equity: who is funding it, what it costs, and where the companies that stall in it actually stall.
01
Executive summary
Free, no form. The findings, the method and every chart that carries one — complete, not a teaser, and the same text that opens the full report.
02
The full report
Sixty-four pages, this first edition, released to a named reader. One form, one reply, and no list you did not ask to be on.
Contact
Have a question about something here, or want to discuss it? We would be glad to hear from you.